Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

July 14, 2017

PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients

News

PDS Biotechnology Corporation and a subsidiary of Merck are collaborating to develop a Phase 2 clinical trial for a combination cancer treatment for people with certain types of head and neck ... Read more

July 7, 2017July 7, 2017

Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows

News

It took longer for advanced melanoma to recur in patients treated with Bristol-Myers Squibb’s Opdivo (nivolumab) than in patients who received Yervoy, according to a Phase 3 clinical trial. The findings ... Read more

May 16, 2017

Granzyme B Protein May Help ID Cancer Patients Who Respond to Immunotherapy Treatments

News

Researchers identified a new biomarker that may help them track cancer response to treatment using a noninvasive positron emission tomography (PET) imaging method. The new method measures granzyme B, a ... Read more

April 27, 2017April 27, 2017

Sellas Testing Galinpepimut-S Vaccine as Potential Therapy in Blood and Solid Cancers

News

Sellas Life Sciences Group is developing the galinpepimut-S vaccine as a potential treatment for patients with cancers ranging from mesothelioma and myeloma to leukemia and ovarian cancer, and is moving forward with ... Read more

April 17, 2017April 17, 2017

Oncolytics Working on Reolysin Immunotherapy Applications After Good Breast Cancer Results

News

Oncolytics Biotech is partnering with other companies to develop immunotherapy and immunomodulatory applications for Reolysin, which improved breast cancer survival rates. A combination of Reolysin and the chemotherapy Taxol (paclitaxel) increased ... Read more

April 5, 2017

Fred Hutchinson Researchers Present New Findings on Cancer Immunotherapy

News

Researchers from the Fred Hutchinson Cancer Research Center talked about recent developments and new research findings in immunotherapy at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention ... Read more

April 3, 2017April 3, 2017

How IDH Protein Mutations Help Cancerous Brain Tumors Evade Immunotherapy

News

Mutations of the isocitrate dehydrogenase (IDH) protein help the cancerous version of a brain tumor known as a glioma evade therapies that involve revving up the immune system, a study ... Read more

March 28, 2017

Chronix Blood Test Can Predict Cancer Patients’ Response to Immunotherapy, Study Shows

News

A blood-based cancer test has shown promise in predicting how solid-cancer patients will respond to immunotherapy, according to the test’s developer, Chronix Biomedical. The study, “Tumor Cell-Free DNA Copy Number Instability ... Read more

January 17, 2017

Hitchhiking Antibodies Can Deliver Disease-Fighting Therapy 100 Times Faster to the Brain

News

Researchers have developed a new method to deliver antibody therapy in the brain, according to a new study. Using modified antibodies that “hitchhike” on a protein that travels from the ... Read more

November 18, 2016November 18, 2016

Genocea’s ATLAS Technology Shows Promise in Advancing Personalized Cancer Vaccines

News

ATLAS technology, by Genocea Biosciences, may be a useful tool to identify specific molecules in cancer patients that can help develop personalized vaccines, according to new research. These findings result ... Read more